Treatment breaks based on ctDNA-MRD status in advanced HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether it's safe to pause treatment for advanced HER2-positive breast cancer when a blood test shows no signs of cancer. The goal is to see if treatment breaks can be taken without the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that has spread or come back (advanced).
- Your cancer has completely disappeared on a scan after at least one line of treatment, and stayed that way for 3 months.
- A blood test (ctDNA-MRD) shows no cancer DNA.
- A blood test (CA153) shows normal levels.
- You are physically able to care for yourself (ECOG score 0-2).
- You are expected to live at least 6 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This trial is testing whether monitoring ctDNA (genetic material from the tumor in your blood) can help guide treatment for HER2-positive breast cancer before surgery. It is for people with early-stage (Stage II or III) disease who have not yet started treatment.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
This study is looking at a test called MRD (minimal residual disease) to see if it can guide decisions about local treatments (like surgery or radiation) for people with breast cancer that has spread to a few spots. It may help doctors know when to use these treatments and when to wait.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.